The stock of Phathom Pharmaceuticals Inc (PHAT) has seen a 7.02% increase in the past week, with a -11.48% drop in the past month, and a 49.75% flourish in the past quarter. The volatility ratio for the week is 7.39%, and the volatility levels for the past 30 days are at 6.94% for PHAT. The simple moving average for the past 20 days is 8.24% for PHAT’s stock, with a 4.74% simple moving average for the past 200 days.
Is It Worth Investing in Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Right Now?
The stock has a 36-month beta value of 0.68. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PHAT is 28.15M, and at present, short sellers hold a 42.74% of that float. On May 09, 2024, the average trading volume of PHAT was 874.77K shares.
PHAT) stock’s latest price update
The stock of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has increased by 3.42 when compared to last closing price of 10.10.Despite this, the company has seen a gain of 7.02% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-09 that Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to loss of $0.89 per share a year ago.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Stifel repeating the rating for PHAT by listing it as a “Buy.” The predicted price for PHAT in the upcoming period, according to Stifel is $24 based on the research report published on May 03, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $26, previously predicting the price at $23. The rating they have provided for PHAT stocks is “Buy” according to the report published on January 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to PHAT, setting the target price at $28 in the report published on August 09th of the previous year.
PHAT Trading at 6.66% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.63% of loss for the given period.
Volatility was left at 6.94%, however, over the last 30 days, the volatility rate increased by 7.39%. Over the last 50 days, in opposition, the stock is trading -2.88% lower at present.
During the last 5 trading sessions, PHAT rose by +7.27%, which changed the moving average for the period of 200-days by -24.08% in comparison to the 20-day moving average, which settled at $9.65. In addition, Phathom Pharmaceuticals Inc saw 14.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Henderson Molly, who sale 3,435 shares at the price of $11.10 back on Apr 08 ’24. After this action, Henderson Molly now owns 95,263 shares of Phathom Pharmaceuticals Inc, valued at $38,128 using the latest closing price.
Curran Terrie, the President and Chief Executive of Phathom Pharmaceuticals Inc, sale 16,851 shares at $9.11 during a trade that took place back on Mar 22 ’24, which means that Curran Terrie is holding 410,784 shares at $153,513 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -245.33 for the present operating margin
- 0.76 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -295.38. The total capital return value is set at -0.45. Equity return is now at value -3489.00, with -69.68 for asset returns.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated 2.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.99. The debt to equity ratio resting at -1.91. The interest coverage ratio of the stock is -7.69.
Currently, EBITDA for the company is -159.05 million with net debt to EBITDA at 1.5. When we switch over and look at the enterprise to sales, we see a ratio of 530.64. The receivables turnover for the company is 0.42for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.25.
Conclusion
To sum up, Phathom Pharmaceuticals Inc (PHAT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
